CompletedPhase 1NCT00716014
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita
Studying Pachyonychia congenita
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pachyonychia Congenita Project
- Principal Investigator
- Sancy A Leachman, MD, PhD, M.DPC Project
- Intervention
- TD101(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2008 – 2008
Study locations (1)
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00716014 on ClinicalTrials.govOther trials for Pachyonychia congenita
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPalvella Therapeutics, Inc.
- RECRUITINGNCT02321423International Pachyonychia Congenita Research RegistryPachyonychia Congenita Project